Skip to main content
. Author manuscript; available in PMC: 2014 Aug 25.
Published in final edited form as: Macromol Biosci. 2013 Jan 11;13(4):464–469. doi: 10.1002/mabi.201200384

Figure 6.

Figure 6

The release profile of bevacizumab from (A) 15 and (B) 20 wt% ESHU systems. The release was sustained over the 17-weeks period with burst releases at the beginning. The 20 wt% ESHU systems resulted in slower release rates, and smaller burst releases due to its higher concentration.